Atrial fibrillation patients undergoing percutaneous coronary intervention: dual or triple antithrombotic therapy with non-vitamin K antagonist oral anticoagulants

About 20% of all atrial fibrillation (AF) patients develop coronary artery disease, which requires coronary stenting [percutaneous coronary intervention (PCI)]. Thus, this subcohort of AF patients may require aggressive antithrombotic therapy encompassing vitamin K antagonist (VKA) or non-vitamin K...

Descripción completa

Detalles Bibliográficos
Autores principales: Goette, Andreas, Vranckx, Pascal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556743/
https://www.ncbi.nlm.nih.gov/pubmed/33088231
http://dx.doi.org/10.1093/eurheart/suaa101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556743/
https://www.ncbi.nlm.nih.gov/pubmed/33088231
http://dx.doi.org/10.1093/eurheart/suaa101

Ejemplares similares